EMERGENT BIOSOLUTIONS INC. COMMON STOCK

Emergent BioSolutions Receives U.S. FDA Approval of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use

20 Jul 2023 18:03:20 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces CEO Transition

27 Jun 2023 07:55:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Finalizes Sale of Travel Health Business to Bavarian Nordic

15 May 2023 07:58:00 By Nasdaq GlobeNewswire

Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 25, 2023 at 9:00am EDT

11 May 2023 06:30:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Reports Financial Results For First Quarter 2023

09 May 2023 16:05:02 By Nasdaq GlobeNewswire

Emergent BioSolutions to Release First Quarter 2023 Financial Results and Conduct Conference Call on May 9, 2023

19 Apr 2023 16:05:00 By Nasdaq GlobeNewswire

U.S. FDA Approves Over-the-Counter Designation for Emergent BioSolutions’ NARCAN® Nasal Spray, a Historic Milestone for the Opioid Overdose Emergency Treatment

29 Mar 2023 09:48:20 By Nasdaq GlobeNewswire

Emergent BioSolutions Reports Financial Results for Fourth Quarter 2022

27 Feb 2023 16:42:44 By Nasdaq GlobeNewswire

Emergent BioSolutions Reports FDA Advisory Committees’ Unanimous Vote in Favor of NARCAN® (naloxone HCI) Nasal Spray for Over-the-Counter Use

15 Feb 2023 17:19:50 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces Sale of Travel Health Business to Bavarian Nordic for Up To $380 Million

15 Feb 2023 02:00:00 By Nasdaq GlobeNewswire

Emergent BioSolutions to Release Fourth Quarter 2022 Financial Results and Conduct Conference Call on February 27, 2023

06 Feb 2023 16:05:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces Organizational Changes as Part of Sharpened Strategic Focus

09 Jan 2023 06:59:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Awarded $379.6 Million Procurement Contract to Supply RSDL© (Reactive Skin Decontamination Lotion Kit) to U.S. Department of Defense

05 Jan 2023 17:30:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for Over-the-Counter NARCAN® (naloxone HCl) Nasal Spray

06 Dec 2022 06:00:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Receives Department of Defense Award to Evaluate Chikungunya Vaccine Candidate in Post-Approval Field Efficacy Study Using Model-Guided Approach

14 Nov 2022 06:30:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Reports Financial Results For Third Quarter 2022

08 Nov 2022 16:16:51 By Nasdaq GlobeNewswire

Emergent BioSolutions Presents Data from Phase 2 Study Evaluating Safety and Immunogenicity of Chikungunya Vaccine Candidate in Prior Recipients of Other Alphavirus Vaccines

01 Nov 2022 16:05:14 By Nasdaq GlobeNewswire

Emergent BioSolutions to Release Third Quarter 2022 Financial Results and Conduct Conference Call on November 8, 2022

18 Oct 2022 06:30:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Completes Acquisition of Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages

26 Sep 2022 16:12:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Initiates Phase 1 Study Evaluating Lassa Virus Vaccine Candidate

06 Sep 2022 06:30:00 By Nasdaq GlobeNewswire